Heart disease has many causes, some carried in our genes and others linked to our lifestyle, but all seemingly complex, hard to pin down and incompletely understood. So the new study published in Nature Genetics is striking for the size and simplicity of the effect it reports.
The mutation, a deletion of 25 letters of genetic code from the heart protein gene MYBPC3, is virtually restricted to people from the Indian subcontinent. But there, Caste and Tribe, Hindu, Muslim, Sikh, Christian and others are all united by this affliction.
The mutation was discovered five years ago in two Indian families with cardiomyopathy, but its significance only became apparent after almost 1500 people from many parts of India, some with heart disease and some without, were studied.
Scientists express this genetic risk as an odds ratio, where 1.2 would be a small effect and 2.0 a large one. For the MYBPC3 mutation, the odds ratio is almost off-scale, a staggering 7.0. Carriers usually show few symptoms until middle age, but after that age most are symptomatic and suffer from a range of effects, at worst sudden cardiac death.
"The mutation leads to the formation of an abnormal protein," explained the study leader, Kumarasamy Thangaraj from the Centre for Cellular and Molecular Biology, Hyderabad, India. "Young people can degrade the abnormal protein and remain healthy, but as they get older it builds up and eventually results in the symptoms we see."
The combination of such a large risk with such a high frequency is, fortunately, unique. "How can such a harmful mutation be so common?" asks Chris Tyler-Smith from The Wellcome Trust Sanger Institute, Hinxton, UK. "We might expect such a deleterious change to have 'died out'.
"We think that the mutation arose around 30,000 years ago in India, and has been able to spread because its effects usually develop only after people have had their children. A case of chance genetic drift: simply terribly bad luck for the carriers."
"The bad news is that many of these mutation carriers have no warning that they are in danger," said Perundurai S. Dhandapany from Madurai Kamaraj University, Madurai, India, "but the good news is that we now know the impact of this mutation."
The lifetime risk of developing heart failure is roughly one in five for a person aged 40 years. Now that this mutation has been identified, there is a new glimmer of hope for some of them. The mutation's effects vary a lot from person to person. Carriers could be identified at a young age by genetic screening and adopt a healthier lifestyle.
"This is a genetic finding of great importance," said Sir Mark Walport, Director of the Wellcome Trust. "Heart disease is one of the world's leading killers, but now that researchers have identified this common mutation, carried by one in 25 people of Indian origin, we have hope of reducing the burden that the disease causes. This research should lead to better screening to identify those at risk and may ultimately allow the development of new treatments."
And perhaps eventually new drugs could be developed to enhance the degradation of the abnormal protein and postpone the onset of symptoms. There is a market of 60 million people waiting.
A common Cardiac Myosin Binding Protein C variant associated with cardiomyopathies in South Asia.
Dhandapany PS et al. (2008)
Published online before print as doi: 10.1038/ng.309
Odds Ratio: the ratio of the odds of an event occurring in one group to the odds of it occurring in another group.
This work was supported by the Wellcome Trust; the Council for Scientific and Industrial Research, India; the Indian Council of Medical Research; the Postgraduate Institute of Medical Education & Research, Chandigarh; the American Heart Association and a Burroughs Wellcome Career Development Award in the Biomedical Sciences.
• Department of Biochemistry, Madurai Kamaraj University, Madurai 625 021, India
• Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
• Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
• Centre for Cellular and Molecular Biology, Hyderabad, India
• Department of Genetics, Osmania University, Hyderabad, India
• Post Graduate Institute of Medical Education and Research, Chandigarh, India
• Faculty of Biological Sciences, Institute of Integrative and Comparative Biology, University of Leeds, Leeds, UK
• Department of Cardiology, Sri Chitra Tirunal Institute of Medical Sciences and Technology, Trivandrum, India
• Department of Pathology (Cardiovascular & Thoracic Division), Seth GS Medical College and KEM Hospital, Mumbai, India
• Department of Cardio-Thoracic Surgery, Rajaji Government Hospital and Madurai Medical College, Madurai, India
• Cardiology Unit, CARE Hospital, The Institute of Medical Sciences, Hyderabad, India
• Department of Cardiac Surgery, Nizams Institute of Medical Sciences, Hyderabad, India
• Institute of Biotechnology and Genetic Engineering (KIBGE), University of Karachi, Karachi 75270, Pakistan
• Department of Anthropology, University of Oxford, Oxford, UK
• Harvard School of Public Health, Boston, Massachusetts, USA
• Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
• Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.
Scientists analysed the DNA of 800 patients at cardiac centres in Hyderabad, Madurai, Thirunalveli, Tiruvanandapuram, Kozhikode, Mumbai, Bhubaneswar, Delhi and Chandigargh.
The Centre for Cellular and Molecular Biology (CCMB) is one of the constituent national laboratories of the Council of Scientific and Industrial Research CSIR, the premier multidisciplinary Research & Development organisation of the Government of India. It was set up as a semi-autonomous Centre in 1977 in Hyderabad, the capital city of Andhra Pradesh, became a full-fledged national laboratory during 1981-82, and was dedicated to the nation on 26 November, 1987 by the then Prime Minister of India late Shri Rajiv Gandhi. The ongoing research programmes at the CCMB are in three major categories - high quality basic research in the frontier areas of modern biology, research relevant to societal needs, and application-oriented research towards commercialisation. These include the areas of biomedicine & diagnostics, evolution & development, gene regulation in prokaryotes and eukaryotes, host-parasite interactions, membrane biology, protein structure, bioinformatics, functional genomics, theoretical biology, etc. CCMB has also taken lead in the dissemination of modern biological information through popularisation of science, science education in schools, and has been a meeting point for art and science.
Madurai Kamaraj University, established in 1966, has 18 Schools comprising 73 Departments. The Directorate of Distance Education of the University has a student strength of about 130,000. The University has 109 affiliated Colleges (9 Autonomous) including other approved institutions and 7 evening colleges. There are centres which promote research potential of teachers. Extension activities are carried out through Department of Youth Welfare, NSS, SC/ST cell and Adult Education programmes.
The Wellcome Trust Sanger Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms and more than 90 pathogen genomes. In October 2006, new funding was awarded by the Wellcome Trust to exploit the wealth of genome data now available to answer important questions about health and disease.
The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending around £650 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing.